Suchergebnisse - "Kurti, Zsuzsanna"

PubPharm (7)

1

Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis - results from multicenter observational cohort

enthalten in: Expert opinion on biological therapy | 2018

von Bálint, A. | Rutka, M. | Kolar, M. | +23

2

Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort

enthalten in: Inflammatory bowel diseases | 2017

von Gonczi, L. | Gecse, K. | Vegh, Z. | +23

3

Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases : results from Central European nationwide cohort

enthalten in: Expert opinion on drug safety | 2017

von Bálint, A. | Rutka, M. | Végh, Z. | +30

4

Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role?

enthalten in: Journal of Crohn's & colitis | 2017

von Gonczi, L. | Vegh, Z. | Golovics, P. | +22

5

Tuberculin Skin Test and Quantiferon in BCG Vaccinated, Immunosuppressed Patients with Moderate-to-Severe Inflammatory Bowel Disease

enthalten in: Journal of gastrointestinal and liver diseases : JGLD | 2015

von Kurti, Z. | Lovasz, B. | Gecse, K. | +12

CommentIn: J Gastrointestin Liver Dis. 2016 Jun;25(2):260-1. - PMID 27308663

6

Low incidence of venous thromboembolism in inflammatory bowel diseases : prevalence and predictors from a population-based inception cohort

enthalten in: Scandinavian journal of gastroenterology | 2015

von Vegh, Z. | Golovics, P. | Lovasz, B. | +7

7

Decreasing trends in hospitalizations during anti-TNF therapy are associated with time to anti-TNF therapy : Results from two referral centres

enthalten in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2014

von Mandel, M. | Balint, A. | Golovics, P. | +11

1
[1]